UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and
mutational load as independent predictors of response to
atezolizumab (atezo) in metastatic urothelial carcinoma (mUC;
IMvigor210).
Authors*: Jonathan E. Rosenberg, Daniel Peter Petrylak, Michiel Simon Van Der Heijden, Andrea Necchi,
Peter H. O’Donnell, Yohann Loriot, Margitta Retz, Jose Luis Perez-Gracia, Joaquim Bellmunt, Petros Grivas,
Richard Wayne Joseph, Lawrence Fong, Edward E. Kadel, Zachary Boyd, Dorothee Nickles,
Garrett Michael Frampton, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, Thomas Powles
Abstract #: 104
Presentation Date/Time: Sunday, June 5: 9:45 - 11:15 AM
Location: Hall D1
Session: Immunotherapy: Now We’re Getting Personal - Using Genomics and Biomarkers to Predict Response
Citation: J Clin Oncol 34, 2016 (suppl; abstr 104)
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring
tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy.
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can
enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant
immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients.
Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying
unbiased approaches to studying antigen-specific responses that are modulated in these patients and are
currently developing biomarkers that may be redictive of clinical efficacy.
http://hemonc.ucsf.edu/fonglab/
*UCSF authors in bold
63